ABEO Abeona Therapeutics Inc.

4.90
-0.1  -2%
Previous Close 5.00
Open 4.95
Price To book 2.65
Market Cap 195.80M
Shares 39,959,000
Volume 185,453
Short Ratio 8.32
Av. Daily Volume 439,740

SEC filingsSee all SEC filings

  1. 8-K - Current report 17518245
  2. S-8 - Securities to be offered to employees in employee benefit plans 162025474
  3. CT ORDER - Confidential treatment order 161999388
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161995980
  5. 8-K - Current report 161986490

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment commenced September 2016.
ABO-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 enrollment completed August 2016. Update provided October 2016 with more analysis due 1Q 2017.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. EQUITY ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  2. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Abeona Therapeutics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 - ABEO
  3. Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
  4. Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
  5. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  6. Lifshitz & Miller Law Firm Announces Investigation of Abeona Therapeutics Inc., Agile Therapeutics, Inc., Alere Inc., Floteck Industries, Inc., Insys Therapeutics Inc., MTS Systems Corporation, Ophthotech Corporation and Teekay Corporation
  7. Lawsuit for Investors in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) announced by Shareholders Foundation
  8. Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017
  9. INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  10. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO) and Lead Plaintiff Deadline - February 14, 2017
  11. SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  12. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO) and Lead Plaintiff Deadline: February 14, 2017
  13. EQUITY ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Abeona Therapeutics Inc. (ABEO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  15. INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  16. ABEO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Abeona Therapeutics Inc. and a Lead Plaintiff Deadline of February 14, 2017
  17. ABEONA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
  18. INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  19. Coverage initiated on Abeona Therapeutics by Jefferies
  20. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Abeona Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 – ABEO

SEC Filings

  1. 8-K - Current report 17518245
  2. S-8 - Securities to be offered to employees in employee benefit plans 162025474
  3. CT ORDER - Confidential treatment order 161999388
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161995980
  5. 8-K - Current report 161986490
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 161975173
  7. 8-K - Current report 161965123
  8. 8-K - Current report 161959258
  9. 424B5 - Prospectus [Rule 424(b)(5)] 161958872
  10. 8-K - Current report 161954925